{"name":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","slug":"futuregen-biopharmaceutical-beijing-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"M108 monoclonal antibody","genericName":"M108 monoclonal antibody","slug":"m108-monoclonal-antibody","indication":"Other","status":"phase_3"},{"name":"Placebo for FG-M108","genericName":"Placebo for FG-M108","slug":"placebo-for-fg-m108","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FG-M108","genericName":"FG-M108","slug":"fg-m108","indication":"Solid tumors (indication under clinical investigation in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"FG-M108","genericName":"FG-M108","slug":"fg-m108","phase":"phase_3","mechanism":"FG-M108 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.","indications":["Solid tumors (indication under clinical investigation in Phase 3)"],"catalyst":""},{"name":"M108 monoclonal antibody","genericName":"M108 monoclonal antibody","slug":"m108-monoclonal-antibody","phase":"phase_3","mechanism":"M108 is a monoclonal antibody that targets a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or block pathogenic signaling.","indications":[],"catalyst":""},{"name":"Placebo for FG-M108","genericName":"Placebo for FG-M108","slug":"placebo-for-fg-m108","phase":"phase_3","mechanism":"This is a placebo, meaning it has no active therapeutic effect.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-17","type":"pipeline","source":"Medical Dialogues","summary":"AbbVie, FutureGen ink pact to develop Next-Generation Therapy for Inflammatory Bowel Disease - Medical Dialogues","headline":"AbbVie, FutureGen ink pact to develop Next-Generation Therapy for Inflammatory Bowel Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOMHd0RmlfMXZWSFM5SzAyZEFhMWhIajZMV0s2LVpxUlBnbkN4ekQxODZCYTZhTUxaSXlUWEZLYUNSU1NOa01ONThkRUJ4dVlCS3RfYUZOZ1dkdmxiRnRMaTZqOHNKNkNFdi0yVjNWRXNpZnNUdXV2b05Wb2xZekVnVjJKbGtLOHIwUXJkT1o4U3BKQnFGbU1KcWNUNEExZw?oc=5","date":"2024-06-14","type":"pipeline","source":"European Pharmaceutical Review","summary":"AbbVie to advance TL1A antibody for IBD - European Pharmaceutical Review","headline":"AbbVie to advance TL1A antibody for IBD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNa1M5RnJUSHlTTWtSN25GTUtQUmplZld5aFdlc2hsa044dThhdzlHSE9INjRnVWRFTENCNUlacm9XcENHRXNRODZFanBGRmljUnZMNnFnRlB3MEdqRDg1MkdORzlvdHc4ZDFBNjRjbU1yb3d3dThhMjVfY052QURRWEl1NHgxNjZldGd3bDNkUk1pUHk2UExVRTYwYk84MTNLTHBBc291Vi1WOEEteXZTTmFPWjc0VWJTUUhsdTJBS0pDZjhrTEh2LVRzMHhUd25tZElSaWVPSGRCQll0M2t1YXFCd1BmWHp1UDF2aVlvaV9qa3R3X0d1VGJXbndYdw?oc=5","date":"2024-06-13","type":"deal","source":"PR Newswire","summary":"AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease - PR Newswire","headline":"AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQWJldlluMm9OUDdTSHdrMzZXaFRKZFE5LTBDRjhkd0ZSbDYyUWpsSUV5X2pob3lxQkc3aU8xeVdZM0dsVnBtUmZiSWlsNUFvSDAzRUpfaTFnNHNXWjFXNWZvc3BISGxYTUttbjY5akRrdmFoUTU3OVQ2ODJLbTRSd0owbkFnNlVmMm9rbnF5MEtjTTZzU0c0TVhTYWY1Sms1b3ZGdzhkMkE?oc=5","date":"2024-06-13","type":"deal","source":"Contract Pharma","summary":"AbbVie, FutureGen Enter License Agreement to Develop FG-M701 - Contract Pharma","headline":"AbbVie, FutureGen Enter License Agreement to Develop FG-M701","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}